Clinical trial
A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Belumosudil in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
NCT02688647 is registered in ClinicalTrials.gov with Kadmon Corporation, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Belumosudil in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- Kadmon Corporation, LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 26, 2016
- Completion date
- April 13, 2021
- Enrollment
- 76 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.